Clinical trial
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
NCT00470613 · SynerGene Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00470613 |
|---|---|
| Title | Safety Study of Infusion of SGT-53 to Treat Solid Tumors |
| Official title | A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of SGT-53 for Infusion in Subjects With Advanced Solid Tumors |
| Lead sponsor | SynerGene Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasm |
| Intervention type | Genetic |
| Interventions | SGT-53 |
| Enrollment | 25 |
| Start date | Feb 1, 2008 |
| Primary completion | Dec 1, 2016 |
| Completion | Dec 1, 2016 |
| First posted | May 8, 2007 |
| Last update posted | Apr 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: